【摘要】 目的：探讨 DNA拓扑异构酶抑制剂在鼻咽癌联合治疗中的应用价值。方法：59例无远处转移的鼻咽癌患者随机分为两组：单放组放疗DT：64～70Gy／6～7周；综合组放疗同单放组，分别在放疗最初和最后2周每日放疗后加用HCPT 6mg／m2。结果：3年生存率和局部复发率单放组为76．7％（23／30）和26．7％（8／30），综合组为82．8％（24／29）和17．2％（5／29），P＞0．05。综合组和单放组肿瘤消退率分别为96．6％（28／29）和80％（24／30），P＜0．05，差异有显著性。综合组毒副反应未增加。结论：羟基喜树碱是一种安全的抗癌药，与放疗联合应用能增效。更多还原

【Abstract】 Objective： To evaluate the effect of hydroxycamptothecin （HCPT） as an inhibitor of DNA topoisomerase I combined with radiotherapy for nasopharyngeal carcinoma （NPC）． Methods： Fifty－nine patients without remote metastasis were divided randomly into two groups． Thirty cases were treated by radiotherapy 64～70Gy／6～7 weeks， while another 29 cases were treated with the same radiation dosage plus HCPT 6mg／m2／d in the first and last two weeks after radiotherapy． Results： The 3－year survival rates of these two groups were 76．7％（23／30） and 82．8％（24／29） respectively． Recurrence in 3 years occurred in 26．7％（8／30） and 17．2％（5／29） of these two groups respectively （P＞0．05）． The efficacy difference between these two groups was significant （P＜0．01）． Conclusion： It suggests that HCPT play an important role in treatment of NPC when combined with radiation．更多还原